Aviceda Therapeutics, a Cambridge, MA-based non-public, clinical-stage biotech firm centered on growing new immunomodulators, raised $207.5M in Collection C financing.
The spherical was led by Omega Funds and TCGX, with participation from Enavate Sciences and Jeito Capital, alongside Longitude Capital, Blue Owl Healthcare Alternatives, and different funding companies.
The corporate intends to make use of the funds to help the continued Section 2b/3 and deliberate pivotal Section 3 scientific trial for AVD-104 in geographic atrophy (GA), a vision-threatening situation secondary to superior age-related macular degeneration, and the growth into different ophthalmic indications.
Aviceda is a non-public, clinical-stage biotechnology firm growing a proprietary Excessive Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the therapy of geographic atrophy secondary to age-related macular degeneration.
Together with AVD-104, Aviceda has a broad pipeline of merchandise in improvement in ophthalmology and a number of different therapeutic areas, together with immunology, fibrosis, oncology, and neurology.
In reference to the Collection C financing, Bernard Davitian of Omega Funds and Chen Yu, M.D., M.B.A., of TCGX have joined Aviceda’s Board of Administrators. Evelyn Harrison, M.B.A., former Chief Working Officer of Iveric Bio (a part of Astellas Pharma Inc.) has additionally joined as an unbiased director, bringing beneficial experience in advancing novel therapies by means of late-stage scientific improvement and commercialization. As well as, Sara Nayeem, M.D. of Enavate Sciences and Rafaèle Tordjman, M.D. Ph.D. of Jeito Capital are appointed Board Observers.
FinSMEs
08/01/2025
